Download the full report
Sinclair Pharma Plc is a pure-play aesthetics business with a highly differentiated portfolio based on improving facial shape and volumisation.
We are proud of what has been achieved at Sinclair Pharma in 2016. Following the disposal of the non-aesthetics assets, the Company is simplified as a fast growth and self-pay aesthetics business. During the period, Silhouette InstaLift® was launched in the US, a direct Brazilian affiliate was formed and revenue growth of 51% was recorded, beating management expectations.
Looking ahead, the Board expects Sinclair to be adjusted EBITDA positive in 2017. Beyond this year, the Board believes that strong core revenue growth augmented by US, Brazil and China launches, combined with operational leverage through rising gross margins and a controlled cost base, will position the Company well to deliver superior returns for shareholders.